A5018965384- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Brain Metastases and Treatment
- Lymphatic System and Diseases
- Estrogen and related hormone effects
- Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Women's cancer prevention and management
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Parasites and Host Interactions
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Cancer Risks and Factors
- BRCA gene mutations in cancer
- Digestive system and related health
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Cancer Research and Treatments
- Parasitic Infections and Diagnostics
AC Camargo Hospital
2018-2024
University of Milan
2024
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo
2024
Universidade Federal de Juiz de Fora
2010-2013
PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with inoperable/metastatic HR+/HER2‒ cancer, who had disease progression on endocrine therapy, for whom therapy was...
Major depressive disorder (MDD) is prevalent and disabling among older adults. Standing on its tolerability profile, vortioxetine might be a promising alternative to selective serotonin reuptake inhibitors (SSRIs) in such vulnerable population.
No presente estudo, as enteroparasitoses mais prevalentes no Brasil foram avaliadas segundo determinantes sociais, aspectos epidemiologicos, clinicos e terapeuticos. Atraves de breve revisao literatura com base nos resultados estudos prevalencia, sao sintetizados achados que corroboram a associacao sua alta prevalencia pobreza ao subdesenvolvimento. Foi dedicada especial atencao doencas tais como esquistossomose, giardiase, ancilostomiase, amebiase, estrongiloidiase, ascaridiase teniase....
Lymphedema is a highly prevalent condition in women who have undergone treatment for breast cancer. negatively affects the quality of life. The objective this study was to estimate prevalence lymphedema and associated factors treated cancer municipality Juiz de Fora.We performed cross-sectional that evaluated 250 were being Pre-screening sample by analysis medical records select met inclusion criteria as follows: had an operation more than 6 months ago; absence active disease, locoregional...
This cross-sectional study objects to measure, subjectively and objectively, the voice life quality of patients with oral cavity, pharyngeal laryngeal cancer, after organ-preservation treatment. 25 cases diagnosed treated at a high complexity oncology center in southeastern Brazil. All had or therapeutic proposal radiotherapy alone simultaneous radiochemotherapy. Acoustic analysis Voice Handicap Index protocol were used measure quality. The data analyzed through χ2, Student's t Kruskal...
Lack of expression the tumour suppressor gene caudal-type homeobox 2 (CDX2) associates with poor outcomes in early stage colorectal cancer (CRC).Yet its prognostic value context other biomarkers metastatic CRC (mCRC) is unknown.Overexpressed cyclooxygenase-2 (COX2) has been reported advanced CRC.However, CDX2 and COX2 relationship mCRC remains undetermined.We aimed to assess their tumours from a clinically characterised cohort influence on overall survival (OS) progression-free (PFS) first...
Brain metastasis (BM) is a rare event in ovarian cancer patients. The current prognostic scores that have been used for other tumors do not account specific characteristics of cancer, such as platinum sensitivity.This retrospective cohort study examined patients with carcinoma and BM who were treated at single institution from January 2007 to December 2017. Clinical data on the diagnosis follow-up collected. Cox regression was evaluate factors overall survival (OS).Of 560 patients, 26...
e16540 Background: Metastatic castration-resistant prostate cancer (mCRPC) phenotype involves androgen-receptor signalling mechanisms that support the use of enzalutamide (EZ) and abiraterone (Abi). These therapies improve overall survival (OS) quality-of-life, with a favourable safety profile. There is no validated data defining best drug or sequence to be used. Methods: A retrospective cohort mCRPC patients (pts) was analysed at AC Camargo Cancer Center. The primary objective compare...
Oncotype DX (ODX) is a validated assay for the prediction of risk recurrence and benefit chemotherapy (CT) in both node negative (N0) 1-3 positive nodes (N1), hormone receptor (HR+), human epidermal growth factor 2-negative (HER2-) early breast cancer (eBC). Due to limited access genomic assays Brazil, treatment decisions remain largely driven by traditional clinicopathologic factors. ODX has been reported be cost-effective different health system, but data are available considering reality...
Abstract Introduction: The long-term severe adverse events associated with anthracyclines, including irreversible cardiotoxicity, myelodysplastic syndromes, and therapy-related leukemias, led researchers to question the risk-benefit of anthracycline-based chemotherapy regimens, especially for patients without axillary lymph node involvement, leading an increasing trend omit anthracyclines in adjuvant treatment. Docetaxel plus cyclophosphamide (TC) has replaced doxorubicin (AC) lower-risk...
e16086 Background: The role of HER2 positive (HER2+) as a prognostic biomarker for gastric/gastroesophageal junction cancer (G-GEJC) is controversial. Recently, the HER2-low (HER2l) concept has emerged and proved to predict response trastuzumab deruxtecan in metastatic scenario. Data on HER2l value are missing. Methods: All consecutive patients with G-GEJC, tested primary tumor or tissue before initiating first-line therapy at A.C. Camargo Cancer Center, were retrospectively recruited....
Abstract Background: Early-stage triple-negative breast cancer (TNBC) is associated with high risk of early recurrence and disease-specific mortality. Studies suggest a sustained clinical benefit in patients TNBC who have pathological complete response (PCR) after neoadjuvant chemotherapy (NACT). In TNBC, the combination immunotherapy based on immune checkpoint inhibitors (anti-PD-1/PD-L1) combined has been shown to be effective both advanced early. early-stage setting, addition...
Abstract Background: The Oncotype Dx (ODX) genomic risk score (RS) has become an essential tool in clinical practice for guiding adjuvant chemotherapy decisions early-stage hormone receptor-positive (HR+), HER2-negative breast cancer (BC). Since some of the genes evaluated RS tests are proliferation-related, use test is less clear tumors with low proliferation, such as histologic grade 1 or those a Ki67-index. In contrast to common understanding, however, ODX determined more strongly by...
Abstract Background: Oncotype DX (ODX) is a genomic signature (GS) for the prediction of risk recurrence and benefit chemotherapy (CT) in both node negative (N0) positive (N1), hormone receptor (HR+), HER2 (HER2-) early breast cancer (eBC). ODX was not an inclusion criterion MonarchE but one Natalee study, which trials most patients received neo-adjuvant chemotherapy. We aim to evaluate proportion potentially eligible adjuvant CDK4/6 inhibitors (CDK4/6i) without CT indication by using...
540 Background: In the MonarchE and Natalee studies, most patients received (neo)adjuvant chemotherapy (CT). precision oncology era, genomic signatures such as Oncotype DX (ODX) can spare many of CT. Our recent Real-World data (RWD) showed that a proportion with hormone receptor positive (HR+) HER2 negative (HER2-) early breast cancer (eBC) would be eligible for adjuvant abemaciclib or ribociclib without indication The main question addressed in this analysis is potential benefit CDK4/6i...
e13039 Background: Early recurrence following treatment for localized breast cancer typically occurs within 5 years, and is commonly linked to high-risk clinicopathologic factors. However, literature focusing on risk factors earlier timeframes scarce, particularly the neoadjuvant population. Therefore, this study aims investigate potential predictors 12 months post-surgery in patients submitted therapy. Methods: This an observational, descriptive, retrospective involving 310 with recurrent...
e13100 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) still represents the best 1st-line choice for hormone receptor (HR) positive(+)/HER2 negative(-) metastatic breast cancer (MBC) patients (pts). Approximately 8% of pts HR+ BC harbors germline BRCA mutation (g BRCAmt). The interaction between Cyclin/CDK pathway, (ER) and Breast Cancer gene 1/2 (BRCA1/2) is complex evidence reported so far, await confirmation in context future randomized clinical...
The standard neoadjuvant therapy for rectal cancer involves fluoropyrimidines and radiotherapy and, most recently, total (TNT). A drug-drug interaction between proton-pump inhibitors (PPI) was suggested, with a negative impact on oncological outcomes in breast, colon gastric cancers. Little is known about such an effect tumours. We aimed to evaluate the of PPI utilisation pathological response after chemoradiation cancer.
The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, has impacted health across all sectors of society. A cytokine-release syndrome, combined with an inefficient response innate immune cells to directly combat virus, characterizes severe form COVID-19. While factors involved in development general population are becoming clearer, identification mechanisms behind disease oncologic patients remains uncertain. Here we evaluated systemic through analysis soluble blood and anti-SARS-CoV-2...